India Rising Stars Outlook 2015: Traditionally Innovation and Drug Discovery Had Taken a Back Seat in the Indian Pharma Industry with a Few Blips Here and There
Traditionally Innovation and drug discovery had taken a back seat in the Indian pharma industry with a few blips here and there. However, there have a been a new generation of entrepreneurs who have who ventured into the drug discovery path backed by VC funding and no pharma heritage ! In this Outlook we highlight the names of some select innovation/drug discovery companies who have successfully raised funds to sustain the research, out-licensed some of their assets or are likely to do so in the next 2-3 years thereby rewarding their investors. . In this Outlook we have initiated coverage on Connexios, Bugworks, Cellworks, Tergene and hope that soon we will be able to expand the universe further.
CONNEXIOUS - CONNEXIOS HAS HAD A BUMPY RIDE LIKE MOST RISING STARS/DRUG DISCOVERY COMPANIES IN THE BIOTECH SECTOR
Technology Platform
Therapy Focus—Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
Key Milestones
Figure 1: PRODUCTS IN PIPELINE- DIABETES
Figure 2: PRODUCTS IN PIPELINE FOR NASH
Figure 3: OTHER PROGRAMS
Appendix 1: Network Biology Platform for Diabetes and fibrosis
Appendix:2 Novel GPR40 agonist
CNX-103: Whole body improvement of metabolic health
Table 1: Differences Between G-Protein Coupled receptor agonists
Table 2: Pipeline Of Gpr Agonist For Treatment Of Type 2 Diabetes
CELLWORKS - CELLWORKS (CW) HAS EVOLVED FROM A SERVICE BASED COMPANY TO A DRUG DISCOVERY /DEVELOPMENT COMPANY ON THE STRENGTH OF ITS PROPRIETARY VIRTUAL PROTOTYPING PLATFORM THAT ALLOWS SIMULATION OF CELL TYPES//DISEASE IN SILICO.
Technology Platform
Pipeline
Figure 1: Simulation Based personalization
Figure 2: Cellworks Therapeutic Programs
BUGWORKS - BUGWORKS IS A VALIDATION OF CELLWORKS SIMULATION IN SILICO TECHNOLOGY PLATFORM WHERE ITS BUGWORKS MICROBIAL PLATFORM (BMP) COMBINES FUNCTIONAL PROTEOMICS WITH SOPHISTICATED SEMICONDUCTOR DESIGNE ENGINEERING TO MODEL AND MANIPULATE VARIOUS BACTERIAL SYSTEMS.
Therapy focus- Serious Hospital Infection
Technology Platform
Need of the Hour- New Targets= New Antibiotic Class
The GAIN Act
Figure 1: Drug Development Success For Tb
Figure 2: Going Way Froward : focus: Helathcare Associated Infections
TERGENE - TERGENE’S FIRST PRODUCT IN DEVELOPMENT IS A VACCINE FOR PNEUMONIA CAUSED BY, STREPTOCOCCUS PNEUMONIA (PNEUMOCOCCOUS). THE AVAILABLE VACCINE THE PNEUMOCOCCAL POLYSACCHARIDE VACCINES (PPV)
Development Strategy and Status-
Long term plans-
Vaccine Market-
Figure 1: sales of currently available vaccines for streptococcus pneumonia
Figure 2: Ww Demand Forecast Of Vaccines For Streptococcus Pneumonia
Figure 3: Vaccine Market
Technology Platform
Therapy Focus—Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
Key Milestones
Figure 1: PRODUCTS IN PIPELINE- DIABETES
Figure 2: PRODUCTS IN PIPELINE FOR NASH
Figure 3: OTHER PROGRAMS
Appendix 1: Network Biology Platform for Diabetes and fibrosis
Appendix:2 Novel GPR40 agonist
CNX-103: Whole body improvement of metabolic health
Table 1: Differences Between G-Protein Coupled receptor agonists
Table 2: Pipeline Of Gpr Agonist For Treatment Of Type 2 Diabetes
CELLWORKS - CELLWORKS (CW) HAS EVOLVED FROM A SERVICE BASED COMPANY TO A DRUG DISCOVERY /DEVELOPMENT COMPANY ON THE STRENGTH OF ITS PROPRIETARY VIRTUAL PROTOTYPING PLATFORM THAT ALLOWS SIMULATION OF CELL TYPES//DISEASE IN SILICO.
Technology Platform
Pipeline
Figure 1: Simulation Based personalization
Figure 2: Cellworks Therapeutic Programs
BUGWORKS - BUGWORKS IS A VALIDATION OF CELLWORKS SIMULATION IN SILICO TECHNOLOGY PLATFORM WHERE ITS BUGWORKS MICROBIAL PLATFORM (BMP) COMBINES FUNCTIONAL PROTEOMICS WITH SOPHISTICATED SEMICONDUCTOR DESIGNE ENGINEERING TO MODEL AND MANIPULATE VARIOUS BACTERIAL SYSTEMS.
Therapy focus- Serious Hospital Infection
Technology Platform
Need of the Hour- New Targets= New Antibiotic Class
The GAIN Act
Figure 1: Drug Development Success For Tb
Figure 2: Going Way Froward : focus: Helathcare Associated Infections
TERGENE - TERGENE’S FIRST PRODUCT IN DEVELOPMENT IS A VACCINE FOR PNEUMONIA CAUSED BY, STREPTOCOCCUS PNEUMONIA (PNEUMOCOCCOUS). THE AVAILABLE VACCINE THE PNEUMOCOCCAL POLYSACCHARIDE VACCINES (PPV)
Development Strategy and Status-
Long term plans-
Vaccine Market-
Figure 1: sales of currently available vaccines for streptococcus pneumonia
Figure 2: Ww Demand Forecast Of Vaccines For Streptococcus Pneumonia
Figure 3: Vaccine Market
